Innate Pharma SA is a global, clinical-stage biotechnology company, which engages in developing immunotherapies for cancer patients. The company is headquartered in Marseille, Paca. The company went IPO on 2006-10-31. The firm identifies and characterizes drug candidates, selects indications, and manages the pre-clinical and clinical development of products. Innate Pharma primarily focuses on the development of new therapeutic solutions and monoclonal antibodies for the treatment of cancer, as well as for the treatment of infectious diseases and chronic inflammatory pathologies. The firm develops two categories of immunotherapies: immuno-modulators and cytotoxic antibodies. The company works in collaboration with Bristol-Myers Squibb for Phase I cancer antibody program and with Novo Nordisk A/S for two antibody programs in inflammation treatment. The firm operates through anti-NKG2A antibody, an immune checkpoint inhibitor ready for Phase II development in oncology from Novo Nordisk. The company also has a multi-product partnership with AstraZeneca.
Follow-Up Questions
IPHYF 股票的价格表现如何？
IPHYF 的当前价格为 $2，在上个交易日 decreased 了 0%。
Innate Pharma SA 的主要业务主题或行业是什么？
Innate Pharma SA 属于 Biotechnology 行业，该板块是 Health Care
